SODIUM VALPROATE IN CHILDHOOD EPILEPSY - …
Sodium valproate page 1 SODIUM VALPROATE IN CHILDHOOD EPILEPSY Report prepared for the World Health Organisation November 2006 1. Summary statement of the proposal for inclusion, change or
Download SODIUM VALPROATE IN CHILDHOOD EPILEPSY - …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Position Paediatric Age Categories to be Used in ...
archives.who.intPosition Paper Paediatric Age Categories to be Used in Differentiating Between Listing on a Model Essential Medicines List for Children
APPLICATION FOR INCLUSION OF RIBAVIRIN IN …
archives.who.int07 Nov. 06 ribavirin.doc 1/31 The Secretary of the Expert Committee on the Selection and Use of Essential Medicines Policy, Access and Rational Use
EXTERNAL REVIEW – THEOPHYLLINE - WHO archives
archives.who.intThis review therefore considers the evidence for the possible deletion of theophylline as a specific oral methylxanthine in relation to the listed
Information to be included with an application for ...
archives.who.intMorphine by mouth Morphine can be given as: a simple aqueous solution of the sulfate or hydrochloride salt every four hours (an antimicrobial preservative may be added); tablets, every 4
Cardiovascular drugs - WHO archives
archives.who.intAntianginal drugs The three main types of angina are: • stable angina (angina of effort), where atherosclerosis restricts blood flow in the coronary vessels; attacks are usually caused by exertion and relieved by rest • unstable angina (acute coronary insufficiency), which is considered to be an intermediate stage between stable angina and myocardial infarction
Gastrointestinal drugs - WHO archives
archives.who.intthose related to NSAID use). Eradication of H. pylori reduces the relapse rate to about 4–8%. This is undoubtedly cost-effective compared to the alternatives of long-term maintenance therapy with low-dose H 2-receptor antagonists or repeated treatment of recurrent ulcers.
Related documents
Crushing tablets – issues to consider - Auspharm
www.auspharmacist.net.auCrushing tablets – issues to consider Au sPharmacist.net.au CE 21/10/2010 Valproate (Epilim) 1 Epilim crushable tablets Antiglycaemic agents
MEDICINES CONTROL COUNCIL - mccza.com
www.mccza.comAdministration Notification of Registration of Medicines 12.52 Notification of Registration Apr10v1.doc May 2010 Page 1 of 4 MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE
Sizwe Medical Fund: CDL Formulary - All Options
www.sizwe.co.zaSizwe Medical Fund: CDL Formulary - All Options This formulary is a summary of treatment covered on the Chronic Disease List (CDL) Formulary.
SCHEDULING STATUS: S3 PROPRIETARY NAME …
www.epilepsy.org.za1 SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): Epilim® Liquid Sugar-free (Liquid) Epilim® CR 200 (Prolonged Release Tablets) Epilim® CR 300 (Prolonged Release Tablets)
SUMMARY OF PRODUCT CHARACTERISTICS - Sanofi
www.sanofi-aventis.co.ukSUMMARY OF PRODUCT CHARACTERISTICS 1. Name of the medicinal product Epilim 100mg Crushable Tablets Epilim 200 Enteric Coated Tablets Epilim 500 Enteric Coated Tablets
GUIDELINES FOR THE MONITORING OF …
www.neneccg.nhs.ukGUIDELINES FOR THE MONITORING OF ANTIMANIC AND PROPHYLACTIC MEDICATION IN BIPOLAR DISORDER NHT Policy number MM-G-023 Date approved by Medicines Management
Epilim - Medsafe Home Page
www.medsafe.govt.nzEpilim Oral NZ Page 3 The lilac tablets have a special coating to stop them dissolving until they have gone through the stomach and into the intestines.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
www.medsafe.govt.nzEpilim should preferably be taken with or after food: the enteric-coated tablet (lilac) must be swallowed whole, if necessary with a little water: the …
SUMMARY OF PRODUCT CHARACTERISTICS - Sanofi
www.sanofi-aventis.co.ukSUMMARY OF PRODUCT CHARACTERISTICS 1 Name of the medicinal product Depakote 250mg Tablets. Depakote 500mg Tablets. 2 …